|
[Greeting] [Title] [Name],
|
|
|
|
Thank you for taking the time to talk about the current Parkinson’s disease (PD) treatment landscape and your patient population.
|
|
|
|
To recap:
|
| •
|
Current treatments do little to address the variable nature of PD1
|
|
•
|
Dosing strategies with current carbidopa/levodopa (CD/LD) tablets put patients at risk of imprecise dosing2
|
|
•
|
Many patients on CD/LD report difficulty managing OFF time and side effects, including dyskinesia3,4
|
|
|
If you have any further questions, don’t hesitate to reach out. Click the button below to learn more about Avion’s commitment to helping the PD community face a brighter future.
|
|
Discover our commitment
|
|
Feel free to reach me at:
|
|
[rep email] | [rep phone number]
|
|
Sincerely,
|
|
[rep name]
|
|
[rep title]
|
|
[rep photo]
|
|
|
References: 1. Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018.
2. Chaudhri K, Kearney M, Di Tanna GL, Day RO, Rodgers A, Atkins ER. Does splitting a tablet obtain the accurate dose?: a systematic review protocol. Medicine (Baltimore). 2019;98(42):e17189. doi:10.1097/MD.0000000000017189. 3. Cabreira V, Soares-da-Silva P, Massano J. Contemporary options for the management of motor complications in Parkinson’s disease: updated clinical review. Drugs. 2019;79(6):593-608. doi:10.1007/s40265-019-01098-w. 4. Tanner CM. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 suppl):S255-S264. doi:10.37765/ajmc.2020.88517.
|
|
|
